Hancock Whitney’s AbbVie ABBV Stock Holding History

Hancock Whitney’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27M	Sell	125,422 -5,589	-4%	-$1.24M	0.47%	54
2025 Q4	$29.9M	Sell	131,011 -131,574	-50%	-$30M	0.54%	42
2025 Q3	$60.8M	Sell	262,585 -3,614	-1%	-$736K	1.11%	15
2025 Q2	$49.4M	Buy	266,199 +216,849	+439%	+$40.3M	0.94%	17
2025 Q1	$10.3M	Sell	49,350 -793	-2%	-$154K	0.34%	64
2024 Q4	$8.91M	Sell	50,143 -5,874	-10%	-$1.08M	0.28%	71
2024 Q3	$11.1M	Sell	56,017 -1,808	-3%	-$337K	0.36%	68
2024 Q2	$9.92M	Sell	57,825 -2,041	-3%	-$338K	0.34%	72
2024 Q1	$10.9M	Sell	59,866 -3,014	-5%	-$519K	0.38%	66
2023 Q4	$9.74M	Sell	62,880 -67,737	-52%	-$9.88M	0.36%	64
2023 Q3	$19.5M	Sell	130,617 -1,519	-1%	-$223K	0.8%	25
2023 Q2	$17.8M	Sell	132,136 -5,926	-4%	-$869K	0.7%	27
2023 Q1	$22M	Sell	138,062 -11,096	-7%	-$1.7M	0.88%	20
2022 Q4	$24.1M	Buy	149,158 +476	+0.3%	+$73K	0.93%	23
2022 Q3	$20M	Sell	148,682 -5,564	-4%	-$798K	0.85%	25
2022 Q2	$23.6M	Buy	154,246 +553	+0.4%	+$84.5K	0.94%	25
2022 Q1	$24.9M	Buy	153,693 +27,596	+22%	+$4.01M	0.85%	27
2021 Q4	$17.1M	Buy	126,097 +1,126	+0.9%	+$133K	0.54%	45
2021 Q3	$13.5M	Sell	124,971 -9,344	-7%	-$1.07M	0.47%	54
2021 Q2	$15.1M	Sell	134,315 -7,265	-5%	-$818K	0.48%	52
2021 Q1	$15.3M	Sell	141,580 -6,970	-5%	-$746K	0.52%	42
2020 Q4	$15.9M	Buy	148,550 +1,046	+0.7%	+$101K	0.53%	42
2020 Q3	$12.9M	Sell	147,504 -5,409	-4%	-$509K	0.48%	48
2020 Q2	$15M	Buy	152,913 +54,113	+55%	+$4.76M	0.58%	40
2020 Q1	$7.53M	Buy	98,800 +11,650	+13%	+$992K	0.3%	92
2019 Q4	$7.72M	Buy	87,150 +6,569	+8%	+$545K	0.25%	111
2019 Q3	$6.1M	Sell	80,581 -95,232	-54%	-$6.53M	0.2%	138
2019 Q2	$12.8M	Buy	175,813 +3,754	+2%	+$295K	0.41%	59
2019 Q1	$13.9M	Buy	172,059 +19,253	+13%	+$1.58M	0.44%	45
2018 Q4	$14.1M	Sell	152,806 -116,180	-43%	-$10.2M	0.48%	35
2018 Q3	$25.4M	Buy	268,986 +130,704	+95%	+$12.4M	0.72%	15
2018 Q2	$12.8M	Sell	138,282 -4,247	-3%	-$415K	0.59%	50
2018 Q1	$13.5M	Sell	142,529 -16,039	-10%	-$1.76M	0.6%	53
2017 Q4	$15.3M	Sell	158,568 -32,654	-17%	-$3.08M	0.63%	38
2017 Q3	$17M	Sell	191,222 -17,815	-9%	-$1.36M	0.72%	12
2017 Q2	$15.2M	Buy	209,037 +196,723	+1,598%	+$13.2M	0.64%	28
2017 Q1	$803K	Sell	12,314 -29,808	-71%	-$1.87M	0.03%	382
2016 Q4	$2.64M	Sell	42,122 -50	-0.1%	-$3.05K	0.1%	237
2016 Q3	$2.66M	Buy	+42,172	New	+$2.73M	0.11%	238
2015 Q4	–	Sell	-44,997	Closed	-$2.45M	–	521
2015 Q3	$2.45M	Buy	+44,997	New	+$2.93M	0.1%	245

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hancock Whitney's ABBV Position: Q1 2026 in Review

Hancock Whitney reduced its AbbVie (ABBV) stake by 4.3% in Q1 2026, selling an estimated $1.24M and leaving 125,422 shares worth $27M. The position accounts for 0.47% of the portfolio, ranked #54.

Hancock Whitney first reported a position in ABBV in Q3 2015 and has held it in 40 quarters since. The position peaked at $60.8M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hancock Whitney held 125,422 shares of AbbVie worth $27M as of Q1 2026.
Hancock Whitney sold 5,589 AbbVie shares in Q1 2026, an estimated $1.24M.
AbbVie made up 0.47% of Hancock Whitney's portfolio in Q1 2026, its #54 holding.
Hancock Whitney first reported a position in AbbVie in Q3 2015 and has held it in 40 quarters since.
Hancock Whitney's AbbVie position peaked at $60.8M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.